000304998 001__ 304998
000304998 005__ 20251005022951.0
000304998 0247_ $$2doi$$a10.1016/j.annonc.2025.09.008
000304998 0247_ $$2pmid$$apmid:41016600
000304998 0247_ $$2ISSN$$a0923-7534
000304998 0247_ $$2ISSN$$a1569-8041
000304998 0247_ $$2altmetric$$aaltmetric:181744969
000304998 037__ $$aDKFZ-2025-01989
000304998 041__ $$aEnglish
000304998 082__ $$a610
000304998 1001_ $$avan Aken, E. S. M.$$b0
000304998 245__ $$aESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors.
000304998 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000304998 3367_ $$2DRIVER$$aarticle
000304998 3367_ $$2DataCite$$aOutput Types/Journal article
000304998 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759230392_31253
000304998 3367_ $$2BibTeX$$aARTICLE
000304998 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304998 3367_ $$00$$2EndNote$$aJournal Article
000304998 500__ $$aepub
000304998 520__ $$aThe combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However, there is a paucity of high-quality toxicity data, leading to an absence of evidence-based guidelines.To address this, ESMO and ESTRO initiated a series of systematic reviews followed by a Delphi consensus process to develop multidisciplinary, evidence-based consensus statements regarding the safety of combining RT with such agents. The current publication describes the combination of RT with immune checkpoint inhibitors (ICIs), vascular endothelial growth factor (receptor) (VEGF(R)) inhibitors, or multitargeted tyrosine kinase inhibitors (TKIs). By systematically covering different drug classes and irradiated areas, 76 clinical scenarios were evaluated during two Delphi rounds with 20 international experts. Safety statements were developed for each scenario, based on the systematic literature reviews.A total of 5,921 records were screened during the systematic literature review process for ICIs, VEGF(R) inhibitors and multitargeted TKIs, and 159 reports were selected for inclusion in the final literature reviews and the database. During the two Delphi rounds, agreement was reached regarding the safety statements for 74 clinical scenarios.Generally, the expected toxicity of combining RT with ICIs is low, particularly for PD-(L)1 inhibitors. For most combinations with VEGF(R) inhibitors and multitargeted TKIs, exercising caution is recommended. The evidence-based safety statements developed during this comprehensive project, provide practical guidance on combining RT with targeted cancer therapies and immunotherapy.
000304998 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304998 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304998 650_7 $$2Other$$aConsensus statements
000304998 650_7 $$2Other$$aImmune checkpoint inhibitors
000304998 650_7 $$2Other$$aRadiotherapy
000304998 650_7 $$2Other$$aSystematic review
000304998 650_7 $$2Other$$aToxicity
000304998 650_7 $$2Other$$aTyrosine kinase inhibitors
000304998 7001_ $$aDevnani, B.$$b1
000304998 7001_ $$aPrelaj, A.$$b2
000304998 7001_ $$aCastelo-Branco, L.$$b3
000304998 7001_ $$aMarijnen, C. A. M.$$b4
000304998 7001_ $$aMartins-Branco, D.$$b5
000304998 7001_ $$aGambacorta, M. A.$$b6
000304998 7001_ $$aLamarca, A.$$b7
000304998 7001_ $$aHarrington, K.$$b8
000304998 7001_ $$aMinniti, G.$$b9
000304998 7001_ $$aHecht, M.$$b10
000304998 7001_ $$aPapamichael, D.$$b11
000304998 7001_ $$0P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aKrause, M.$$b12$$udkfz
000304998 7001_ $$aCathomas, R.$$b13
000304998 7001_ $$aLindberg, K.$$b14
000304998 7001_ $$aO'Cathail, S. M.$$b15
000304998 7001_ $$aNestle, U.$$b16
000304998 7001_ $$aBarriuso, J.$$b17
000304998 7001_ $$aNowicki, S.$$b18
000304998 7001_ $$0P:(DE-HGF)0$$aRödel, C.$$b19
000304998 7001_ $$aBoot, P.$$b20
000304998 7001_ $$aBelka, C.$$b21
000304998 7001_ $$aRicardi, U.$$b22
000304998 7001_ $$aLordick, F.$$b23
000304998 7001_ $$aDe Ruysscher, D.$$b24
000304998 7001_ $$aPentheroudakis, G.$$b25
000304998 7001_ $$ade Jong, M. C.$$b26
000304998 7001_ $$aGandhi, A. K.$$b27
000304998 773__ $$0PERI:(DE-600)2003498-2$$a10.1016/j.annonc.2025.09.008$$gp. S0923753425047192$$pnn$$tAnnals of oncology$$vnn$$x0923-7534$$y2025
000304998 909CO $$ooai:inrepo02.dkfz.de:304998$$pVDB
000304998 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000304998 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000304998 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304998 9141_ $$y2025
000304998 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN ONCOL : 2022$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000304998 915__ $$0StatID:(DE-HGF)9950$$2StatID$$aIF >= 50$$bANN ONCOL : 2022$$d2025-01-07
000304998 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK Koordinierungsstelle Dresden$$x0
000304998 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x1
000304998 980__ $$ajournal
000304998 980__ $$aVDB
000304998 980__ $$aI:(DE-He78)DD01-20160331
000304998 980__ $$aI:(DE-He78)FM01-20160331
000304998 980__ $$aUNRESTRICTED